Andrew A Davis
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew A Davis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07619365 · Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerWashington University School of Medicine · not yet recruiting · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Optimizing HER2 modulation in HER2-low breast tumors to enhance ADC therapyR01CA309209 · NCI · WASHINGTON UNIVERSITY · fiscal years 2026 · $645,323 awarded in 2026Same name and institution; not confirmed by an ID
- EGF RECEPTOR CONTROL OF RETINAL CELL NUMBERF32EY006748 · NEI · UNIVERSITY OF WASHINGTON · fiscal years 1996 to 1998 · $30,492 awarded in 1998Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:13 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed